Photo taken from Vivek Subbiah/LinkedIn
Oct 18, 2023, 16:54
Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“BRAFV600E alterations are prevalent across multiple tumors and is a tissue agnostic precision medicine target. Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers:
- Anaplastic thyroid carcinoma (n = 36),
- Biliary tract cancer (n = 43) adenocarcinoma of the small intestine (n = 3),
- Low-grade glioma (n = 13),
- High-grade glioma (n = 45)
- Hairy cell leukemia (n = 55)
- Multiple myeloma (n = 19).
(both solid+ liquid tumors) – BRAF + Mutiple myeloma as well
Link to Nature Medicine paper.”
Source: Vivek Subbiah/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33